Month: 2025-08

HONG KONG, Aug 5, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s National Medical Products Administration (NMPA). This approval for production expansion will further boost capacity and increase product supply, enabling a more efficient response to the growing clinical demand in China and across Asia.NEFECON® is the first and only etiological treatment for IgA nephropathy (IgAN) to receive full approval in China, the United States, and Europe, serving as a foundational first-line therapy for patients with IgAN. Since its initial approval in China in November 2023, NEFECON® was subsequently included in the National Reimbursement Drug List (NRDL) in November 2024, and received full approval from the NMPA in May 2025, irrespective of proteinuria levels, benefiting most individuals living with IgAN.NEFECON® specifically modulates the mucosal immune system in the gut to reduce the formation of pathogenic galactose-deficient IgA1 (Gd-IgA1) that trigger IgAN. Results from the Phase 3 clinical study NefIgArd demonstrated that NEFECON® reduces the decline in kidney function by 50%. Results from Phase 3 clinical study NefIgArd of the Chinese population shows that NEFECON® reduces kidney function decline by 66%, and delays disease progression to dialysis or kidney transplantation by 12.8 years.“The expansion of our NEFECON® production capacity will help better meet the growing clinical treatment needs of IgAN patients in China.” Said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “China has one of the highest rates of primary glomerular disease in the world, with more than 5 million patients estimated to be living with IgAN and over 100,000 new cases diagnosed each year. Chinese IgAN patients generally experience faster disease progression and poorer prognosis, highlighting a significant unmet medical need.As the only etiological treatment for IgAN currently recommended by both international and Chinese guidelines, the expansion of NEFECON® production will further accelerate the uptake of etiological treatment, enabling more patients to access standardized treatment earlier to delay disease progression and protect kidney function. We will continue to enhance the accessibility and affordability of NEFECON®, supporting its advancement from ‘changing the treatment landscape’ to ‘redefining the standard of care’.”NEFECON®, as the only in-disease IgAN treatment has been included in the KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (public review draft), making it the only targeted therapy endorsed by both international and Chinese guidelines. NEFECON® has been approved across all Everest Medicines’ territories, including mainland China, Hong Kong SAR, Macau SAR, Taiwan region, China, as well as Singapore and South Korea, and continues to expand its therapeutic impact across Asia.As production capacity continues to grow and supply capabilities improve, NEFECON® is well positioned to benefit a broader patient population by accelerating the uptake of etiological treatment, enabling more patients to access standardized care earlier to delay disease progression and preserve kidney function. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月5日 - (亞太商訊 via SeaPRwire.com) - 今日，雲頂新耀（HKEX: 1952.HK）宣布旗下中國首個且唯一獲得完全批准的IgA腎病對因治療藥物耐賦康®（布地奈德腸溶膠囊）擴產補充申請已正式獲得中國國家藥品監督管理局（NMPA）批准，標志著該產品在中國市場的供應能力將實現進一步提升。此次擴產獲批將進一步提升產能，增加產品供應，更高效地響應中國及亞洲地區對耐賦康®的持續增長的臨床需求。為更多IgA腎病患者提供及時、創新的治療選擇。作為全球首個且目前唯一在中國、美國和歐洲獲得完全批准的IgA腎病對因治療藥物，自2023年11月在中國獲批以來，耐賦康®迅速確立了其作為IgA腎病一線治療的基石地位，並於2024年11月被納入國家醫保目錄。2025年5月，該藥品進一步獲得NMPA完全批准，適應症不再受限於蛋白尿水平，顯著擴大了適用患者群體。據悉，耐賦康®通過特異性調節腸道黏膜免疫，減少誘發IgA腎病的半乳糖缺陷的IgA1（Gd-IgA1）產生，從而阻止下遊的病理途徑，最終有效控制蛋白尿並保護腎功能。在全球III期NefIgArd研究中，耐賦康®能使腎功能下降風險降低50%，中國人群數據分析顯示，能減少66%腎功能下降，疾病進展至透析或腎移植的時間延緩12.8年。雲頂新耀首席執行官羅永慶表示：「本次產品生產產能的提高，將更好滿足亞洲地區IgA腎病患者日益增長的臨床治療需求。IgA腎病在亞洲高發，其中中國是全球原發性腎小球疾病發病率最高的國家之一，估計目前有超過500萬名IgA腎病患者，每年新增確診患者超過10萬例。中國IgA腎病患者的疾病進展快、預後差，臨床尚存在巨大未滿足的治療需求。作為目前唯一獲國內外指南共同推薦的IgA腎病對因治療藥物，耐賦康®的擴產將加速對因治療的普及，助力更多患者盡早開啟規範治療、延緩疾病進展、保護腎功能。我們也將持續推動耐賦康®的可及性與可負擔性，加速其從『改變治療格局』邁向『重塑治療標准』。」憑借創新的作用機制和突出的臨床優勢，耐賦康®先後被納入《2024版KDIGO IgA腎病和IgA血管炎臨床管理實踐指南（公開審查版）》以及《中國成人IgA腎病及IgA血管炎臨床實踐指南（預審版本）》，成為目前唯一同時獲國際與國內指南推薦的IgA腎病對因治療藥物。這不僅改變了傳統的IgA腎病治療方案，對因治療和支持治療需同時進行，並確立了耐賦康®作為IgA腎病一線治療的基石地位。目前，耐賦康®已在雲頂新耀所有授權區域（包括中國大陸、中國香港、中國澳門、中國台灣、新加坡及韓國）獲得批准,在亞洲地區持續拓展其治療影響力。隨著產能的持續擴張和市場供應能力的增強，耐賦康®有望造福更多患者，推動IgA腎病治療邁入精准治療新階段。 Copyright 2025 亞太商訊 via SeaPRwire.com.

NEW YORK, Aug 4, 2025 - (ACN Newswire via SeaPRwire.com) - Traveler Care, a breakthrough medical dispatch platform that brings urgent care directly to travelers in hotels, Airbnbs, and vacation rentals, has officially launched worldwide - offering travel insurance companies a high-impact solution to reduce avoidable emergency room and hospital claims.Traveler care traveler.care home pageA Concierge Alternative to the Emergency RoomTraveler Care connects travel insurers and their policyholders to a network of licensed, on-call providers who visit travelers in their accommodations - typically within 60-90 minutes. Conditions such as flu, food poisoning, dehydration, allergic reactions, UTIs, sprains, and wound care are treated on-site, eliminating the need for an ER visit."In most cases, travelers just need a doctor - not a hospital admission," said Eli Ofel, founder of Traveler Care. "We've built a scalable, insurer-ready solution that saves money and delivers a far better traveler experience."Reduce Claims by $10,000+ Per VisitOn average, a non-emergency ER visit costs travel insurers $13,000 to $17,000. Traveler Care treats the same conditions in-room for $1,700 to $3,000 - including diagnostics like mobile X-ray, ultrasound, IV therapy, and wound treatment.Pilot results have shown:- 83% reduction in ER claim volume- $10,000+ savings per case avoided- Higher satisfaction scores among travelersBuilt for Travel Insurance PartnersTraveler Care is fully designed for insurance integration - with white-label and API options available for TPAs, underwriters, and global assistance networks.Platform features:- Nationwide U.S. coverage (with international expansion underway)- A robust dispatch network, for example companies like Leaa Health, Sickday, Heal, DocGo and more, any location that the travel insurance is experiencing high volume travel care will create a solution for that particular location within 60 days.- HIPAA-compliant documentation + one-click claims integration- Supports care delivery to hotels, Airbnbs, resorts, and serviced apartmentsNow Onboarding Insurance Companies Worldwide"We believe travel insurance companies shouldn't just pay for care - they should deliver it smarter," said Ofel. "With Traveler Care, you lower claims without compromising care."Insurance providers, TPAs, and global assistance companies are invited to partner and deploy in-room urgent care as part of their medical benefit stack.ContactTo schedule a private demo or receive our ROI case study:Visit www.traveler.careEmail: partners@traveler.carePhone: +1 (347) 733-0563About Eli OfelEli Ofel is a serial entrepreneur and visionary behind multiple AI- and tech-powered platforms in healthcare, finance, and transportation. He is the founder and CEO of Traveler Care, Run.Vet, Leaa Health, 02.Market, and Lender.Market. With over 20 years of experience in healthcare operations, insurance workflows, and mobile logistics, Ofel brings a proven ability to bridge patient needs with scalable platform solutions - saving time, money, and lives.Contact InformationEli OfelCEOeli@traveler.care3477330563SOURCE: Traveler care Copyright 2025 ACN Newswire via SeaPRwire.com.

Boca Raton, Florida--(ACN Newswire via SeaPRwire.com - August 4, 2025) - Atlas Lithium Corporation (NASDAQ: ATLX) ("Atlas Lithium" or "Company"), a leading lithium development company, is pleased to announce that SGS Canada Inc. ("SGS") has completed the Definitive Feasibility Study ("DFS") for the Company's 100%-owned Neves Lithium Project ("Project"), a technical report prepared under the U.S. guidelines of Item 1300 of Regulation S-K ("Regulation S-K 1300"). This hard-rock Project is well-suited to being a low-cost open-pit mining operation, as its spodumene deposits are located relatively close to the surface. Located in the state of Minas Gerais, Brazil, the Project encompasses 4 of the 98 mineral rights for lithium owned by Atlas Lithium. As detailed in the DFS, the Neves Project is expected to deliver strong financial metrics with an internal rate of return ("IRR") of 145%, payback in 11 months from the start of operations, and an after-tax net present value ("NPV") of $539 million. Importantly, the DFS estimates the Neves Project to have operational production costs of only $489 per tonne of lithium concentrate, positioning Atlas Lithium among the world's lowest-cost producers. Complete details of these metrics can be found in the DFS, filed with the Securities and Exchange Commission as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Marc-Antoine Laporte from SGS serves as the Qualified Person for the DFS under Regulation S-K 1300. SGS is well-known as a global leader in testing, inspection, and certification services for mineral properties and projects.Industry-Leading Capital Efficiency and Low Operating CostsThe DFS supports that expected direct capital expenditures of $57.6 million will be needed for the implementation of the Project, by far the lowest such capital costs among other announced projects in Brazil. Notably, Atlas Lithium has already invested approximately $30 million in acquiring and transporting the Project's newly fabricated dense media separation ("DMS") plant to Brazil, as previously reported. The Company has secured two non-dilutive pre-payment agreements for its lithium concentrate totaling $40 million and has received additional funding interest from other parties, including 10-year debt financing options, any of which could support the Project's capital requirements.The Company believes that the DFS validates the Project's strong economics, positioning it among the most capital-efficient and lowest-cost hard-rock lithium developments globally. The Project will employ proven DMS technology, with comprehensive metallurgical testing demonstrating an expected robust lithium recovery rate of 61.7% to produce high-quality, low-impurity lithium concentrate. This relatively straightforward, low-risk DMS processing methodology minimizes technical complexity and operational risk while enabling a low environmental footprint.Atlas Lithium's mineral right to be mined, as detailed in the DFS, received its "Portaria de Lavra" (mining concession) status from Brazil's Ministry of Mines and Energy on May 27, 2025 — the highest level of titleship in Brazil and one that allows continuous mining operations. Multiple deposit areas within the Project remain open for resource expansion along strike and at depth and are thus expected to extend the life of mine. Additionally, numerous high-potential geological targets remain within the Project's mineral rights, providing compelling opportunities for future exploration.Located in the established Araçuaí Pegmatite District in the Vale do Jequitinhonha, often called Lithium Valley, the Project benefits from favorable infrastructure, including proximity to transportation networks, water resources, and skilled labor. The Project qualifies for tax incentives from the Superintendency for the Development of the Northeast (SUDENE), as promulgated by Brazil's Ministry of Integration and Regional Development, reducing the corporate tax rate from 34% to 15.25% and further enhancing profitability."The DFS indicates potentially outstanding returns for our initial vision of developing a focused, near-term, profitable lithium production asset with minimal capital requirements," said Marc Fogassa, Chairman and CEO of Atlas Lithium. "The combination of our low capital intensity and rapid payback period is expected to create exceptional value for our shareholders while positioning Atlas Lithium to benefit from future organic expansion opportunities at Neves and other high-potential lithium areas that we own. Importantly, we are creating many quality employment opportunities in the Vale do Jequitinhonha region, representing a significant societal contribution of our Project."Experienced Leadership Driving Project ImplementationFollowing his leadership role in collaborating with SGS on the DFS, project implementation activities are being supervised by Eduardo Queiroz, Atlas Lithium's Project Management Officer (PMO) and Vice President of Engineering. Mr. Queiroz has more than two decades of hands-on experience managing complex, large-scale mining projects."The DFS demonstrates the technical robustness of the Project, with proven DMS technology and comprehensive metallurgical test work validated by SGS, a premier firm in the lithium space," said Mr. Queiroz. "With our processing plant fully fabricated and paid for, and now with the DFS in hand, we have systematically de-risked the Project. I am excited to lead the implementation phase of Atlas Lithium's journey to becoming a lithium producer."Salinas and Clear: The Next Expansion FrontierAtlas Lithium is strategically positioned to capitalize on its extensive regional lithium exploration portfolio in Brazil, particularly through advancement of its Salinas Project and Clear Project, both 100% owned by the Company. Atlas Lithium's Salinas Project is just 5 miles east of the Colina lithium asset previously owned by Latin Resources — a major factor in Pilbara Minerals's acquisition of that company in 2024 for approximately $370 million. At the Salinas Project, Atlas Lithium has already achieved promising initial results, including the discovery of spodumene-rich pegmatites very close to the surface, and highly positive results from soil geochemistry and from LIDAR geological mapping.Atlas Lithium's Clear Project is located less than 4 miles from Sigma Lithium's operating lithium mine, and represents significant untapped potential with highly positive results from soil geochemistry and from LIDAR geological mapping.Diversification in Critical MineralsAtlas Lithium also owns approximately 30% of Atlas Critical Minerals Corporation (OTCQB: JUPGF), a separate company with exploration programs in uranium, rare earths, titanium, and graphite.About Atlas Lithium Corporation Atlas Lithium Corporation (NASDAQ: ATLX) is a lithium development company focused on advancing its Neves Project to production. The Neves Project's Definitive Feasibility Study demonstrates excellent economics with a 145% IRR, $539 million NPV, and an 11-month payback. The Neves Project has received operational permitting, and its dense media separation plant has been acquired and transported to Brazil. With approximately 539 square kilometers of lithium mineral rights, Atlas Lithium owns the largest lithium exploration footprint in Brazil among publicly listed companies. Additionally, Atlas Lithium currently holds an approximate 30% ownership stake in Atlas Critical Minerals Corporation (OTCQB: JUPGF).Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based upon the current plans, estimates and projections of Atlas Lithium and its subsidiaries and are subject to inherent risks and uncertainties which could cause actual results to differ from the forward-looking statements. Such statements include, among others, those concerning market and industry segment growth and demand and acceptance of new and existing products; any projections of production, reserves, sales, earnings, revenue, margins or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding future economic conditions or performance; uncertainties related to conducting business in Brazil, as well as all assumptions, expectations, predictions, intentions or beliefs about future events. Therefore, you should not place undue reliance on these forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: Atlas Lithium's ability to successfully assemble and begin operations of its modular plant; reaching estimated production, development plans and cost estimates for the Neves Lithium Project as reported in the Definitive Feasibility Study (the "DFS"); discrepancies between actual and estimated mineral reserves and mineral resources, between actual and estimated development and operating costs, and between estimated and actual production; results from ongoing geotechnical analysis of projects; business conditions in Brazil; general economic conditions, geopolitical events, and regulatory changes; availability of capital; Atlas Lithium's ability to maintain its competitive position; manipulative attempts by short sellers to drive down our stock price; and dependence on key management.Additional risks related to the Company and its subsidiaries are more fully discussed in the section entitled "Risk Factors" in the Company's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 28, 2025, and in the Company's Form 10-Q filed with the SEC on August 4, 2025. Please also refer to the Company's other filings with the SEC, all of which are available at www.sec.gov. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.Investor RelationsGary GuytonVice President, Investor Relations+1 (833) 661-7900 gary.guyton@atlas-lithium.comhttps://www.atlas-lithium.com/@Atlas_LithiumTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/261106 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月4日 - (亞太商訊 via SeaPRwire.com) - 持有花園道三號及朗豪坊物業的冠君產業信託（股份代號：2778），於8月1日成功舉辦「ESG Gala」壓軸活動--青少年電影放映會及職業生涯分享會。本屆「ESG Gala」活動以「創新．啟發．融合」為主題，透過一系列專題分享、互動體驗以及藝術展覽，吸引逾千名青年及業界人士參與，展現信託秉持綠色營運與共融理念，推動價值共創，實踐多贏局面。信託積極響應香港政府「共創明『Teen』計劃」，致力支援來自弱勢社群家庭青少年的身心發展，啟發他們探索更廣闊的未來發展方向。作為本屆「ESG Gala」的壓軸活動，信託在朗豪坊Gala Cinema包場舉辦電影放映會，邀請約160名青少年學員及來自18間大型企業的義務友師們，一同欣賞動畫電影，現場充滿歡樂與感動。放映會後，信託特別邀請本地知名動畫師崔氏兄弟與在場青少年分享職涯規劃，引領青少年勇於追夢，探索多元發展方向，促進社會向上流動。冠君產業信託行政總裁侯迅女士表示：「我們很高興與一眾青少年聚首一堂，希望今天的活動及分享能夠啟發青少年，勇敢嘗試、探索、發掘更多的可能性。未來屬於年輕一代，而我們致力成為連接夢想與機遇的平台，與青年同行，共同成長。」本地動畫師崔氏兄弟表示：「很榮幸能夠與青少年分享動畫創作及職涯經驗。我們相信，只要保持好奇心和堅定信念，勇於嘗試，每位年輕人都能找到屬於自己的舞台，開創無限未來。」信託連續三年舉辦ESG主題活動，吸引來自學界、商界、社福界的持份者積極參與與交流，累計參與人次突破50,000，有效加快整個價值鏈的轉型步伐，進一步擴大可持續發展的正面效益。圖片說明：冠君產業信託於 ESG Gala 壓軸舉辦電影放映會，免費邀請約160名共創明「Teen」青少年學員和義務友師一同欣賞動畫電影。本地知名動畫師崔氏兄弟於放映會後與青少年互動，鼓勵年輕人勇敢追夢，探索多元未來。政府共創明「Teen」的學員，包括多元族裔青少年，於朗豪坊參與電影放映會。關於冠君產業信託（股份代號：2778）冠君產業信託擁有及投資提供租金收入的寫字樓及零售物業。信託主要投資位於優越地點的甲級商用物業。現時擁有花園道三號及朗豪坊兩幢位於香港的地標性物業，並以合資股權形式擁有位於倫敦市中心的 66 Shoe Lane，總樓面面積約300 萬平方呎，讓投資者可直接投資於優質甲級寫字樓及零售物業。信託自2023年榮獲全球房地產GRESB可持續的最高五星級別。冠君產業信託管理人乃鷹君資產管理（冠君）有限公司，為鷹君集團的成員。網站: www.championreit.com Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月4日 - (亞太商訊 via SeaPRwire.com) - 華營建築有限公司（「華營建築」）憑藉在企業社會責任（CSR）的持續投入，於建造業議會主辦的「建造業義工嘉許禮2025」中，榮獲三項殊榮，包括「CISVP全年最積極企業大獎 - 企業組（組別二）金獎」、「評審嘉許 - 卓越建造業義工（優異獎）」及「評審嘉許 - 優秀社福機構協作（優異獎）」。這一系列榮譽，充分印證華營建築將關愛文化融入企業血脈，並與員工、社區夥伴攜手貢獻社會的堅定承諾。「建造業義工嘉許禮」由議會轄下的「建造業運動及義工計劃」（CISVP）舉辦，旨在表揚及肯定業界義工及機構的無私奉獻，並推廣「建義勇為」的關愛精神，共建和諧社會。 「CISVP全年最積極企業大獎」是嘉許企業在過去一年積極組織及參與義工服務的殊榮；而「卓越建造業義工」及「優秀社福機構協作」兩項評審嘉許，則分別表彰了義工個人的傑出貢獻，以及公司與社福界夥伴的成功合作模式。 華營建築囊括此三項大獎，是對公司從企業層面、員工參與到跨界協作的全方位義工服務體系的權威認可。華營建築董事總經理潘樹杰先生強調：「我們深信，企業的價值不僅在於建造優質的樓宇，更在於建設一個充滿關愛的社會。這些獎項屬於每一位利用工餘時間服務社群的華營同事，也屬於與我們並肩同行的社福機構夥伴。這份榮譽將激勵我們繼續秉持『以人為本』的理念，發揚『建義勇為』的精神，將專業與愛心結合，為香港社會注入更多正能量。」華營建築在「建造業義工嘉許禮2025」上，榮獲「CISVP全年最積極企業大獎 - 企業組（組別二）金獎」企業的關懷精神，不僅體現在對外的社區服務，更植根於對內的員工福祉。作為此理念的生動實踐，公司早前舉辦的年度「炎夏展關懷」行動，便是一個具體例子。 期間，管理層親率團隊深入各大工地，為前線工友派發防暑裝備與清涼物資，以務實舉措守護勞動者的職場健康。 這項行動與公司推動義工服務的初心一脈相承，皆以人為本，旨在為勞動者及社區民眾創建一個安全、健康、有尊嚴的環境。在「炎夏展關懷」行動中，華營建築管理層與前線工友親切互動。感謝工友們的辛勤付出，你們是我們最重要的合作夥伴。面向未來，華營建築將繼續堅守企業公民責任，深化與各界持份者的合作，並鼓勵更多員工投身義工行列。公司將承載著業界的嘉許與社會的期望，繼續在拓展業務的同時，積極回饋社會，為香港的繁榮與和諧發展貢獻力量。在「建造業義工嘉許禮2025」現場，我們一同見證榮譽的誕生，分享每一份喜悅，並為業界的關愛精神和卓越成就感到驕傲。關於華營建築有限公司華營建築有限公司於1967年成立，為華營建築集團控股有限公司的間接全資附屬公司，在香港從事建築業多年，累積豐富本地建築市場經驗，成為一所具聲譽及客戶信賴的承建商。2014年1月，浙江省建設投資集團有限公司收購華營，成為華營的最終母公司。2019年10月，華營建築集團控股有限公司於香港聯交所主板上市。華營建築對外承接多項具代表性之工程項目，當中包括白田邨第十三期公營房屋重建項目、啟德1E區1號公營房屋發展項目、運用組裝合成建築法(MiC) 的洪水橋及荃灣聯仁街過渡性房屋項目、觀塘市中心第二及第三區住宅綜合發展項目、灣仔軒尼詩道1號(One Hennessy)、麗晶酒店翻新工程、多座數據中心、各大專院校，包括香港中文大學、香港科技大學和香港理工大學在內的教學及科研樓、宿舍等，所承建之項目屢獲殊榮。媒體聯繫黃先生電話：+852 3750 5785郵箱：media@czcgl.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月4日 - (亞太商訊 via SeaPRwire.com) - 由大灣區經貿協會、大灣區學院、中華環保聯合會及Absolute Pure EnviroSci Limited（「APEL」）旗下「香港科技大學--APEL環境科學健康與環境創新聯合實驗室」聯合主辦的「化廢為寶、產業升級、灣區共創」科技論壇於2025年7月29日在香港盛大舉行，吸引近百位科創界權威、行業領袖及商界精英共襄盛舉，聚焦固廢治理與新材料應用、智能製造賦能工業升級、低碳建材創新應用、粵港澳政策協同及智能水質監測與淨化科技等前沿議題，以科技創新驅動循環經濟，為大灣區可持續發展注入新動能。本次活動特邀多位行業標杆人物發表演講，包括香港特別行政區政府環境及生態局副局長黃淑嫻女士, JP、湖南建投六建集團副總經理劉坤先生、APEL主席鍾偉强博士、大灣區經貿協會榮譽會長及大灣區榮譽院士鄭文聰教授, BBS, MH, JP、中華環保聯合會副主任陳永暉先生，以及香港科技大學化學及生物工程學系、環境及可持續發展學部教授楊經倫教授。多位嘉賓從政策、產業、綠色創新與區域協作等多角度剖析灣區機遇，為大灣區高質發展建言獻策。香港特別行政區政府環境及生態局副局長黃淑嫻女士表示：「為推動低碳轉型並及時把握綠色發展帶來的經濟機遇，香港已與粵港澳大灣區內地城市建立固定的合作機制，積極探索「無廢城市」區域共建模式。兩地以區域優勢互補策略，推動大灣區可回收物料的資源化利用，共同發展循環經濟。通過創新、合作和政策引導，我們將能把環保挑戰轉化為新的機遇。希望今天的討論能夠激發更多的創新思維和合作機會，讓我們攜手共創綠色未來。」湖南建投六建集團副總經理劉坤先生指出：「科技的未來屬於敢於突破的實踐者，我們能將『化廢為寶 』的智慧、『產業升級』的魄力、『港區共創』的格局融成一體，充分發揮投資與基建的多領域優勢，為香港可持續高質量發展做出貢獻。」APEL 主席鍾偉强博士表示：「科技是推動新時代經濟轉型和提升競爭力的關鍵引擎。我們要善用科技力量，實踐『化廢為寶』，推動產業升級和綠色發展。香港憑藉企業家精神、創新技術、完善基建和國際連繫，具備打造世界級產業集群的獨特優勢。在新時代的發展格局中，官、產、學、研、投五方應緊密合作，推動智能製造、綠色科技和高端製造業，加強與大灣區城市的聯動。APEL 將繼續配合政府政策，促進科技融合與環保創新，助力香港成為新型工業化的典範，為本地以至全球的可持續發展注入新動力。」大灣區經貿協會榮譽會長及大灣區榮譽院士鄭文聰教授表示：「我們深信科技創新是推動區域經濟高質量發展的核心動力，今天的論壇正是我們邁向綠色、智慧、可持續未來的重要一步。通過智能化的固廢處理和資源再生技術，不僅能大幅減少廢棄物對環境的壓力，還能將其轉化為高附加值的新材料，推動綠色產業鏈的延伸，有效助力國家『碳達峰、碳中和』目標的實現。」本次活動吸引近百位科創界權威、行業領袖及商界精英共襄盛舉，出席嘉賓包括香港特別行政區政府環境及生態局副局長黃淑嫻女士, JP（右五）、湖南建投六建集團副總經理劉坤先生（右四）、義合控股有限公司主席詹燕群先生（左五）、APEL主席鍾偉强博士（右三）、APEL董事楊學光博士（左四）、大灣區經貿協會創辦人賴國偉博士（左一）、大灣區經貿協會榮譽會長及大灣區榮譽院士鄭文聰教授, BBS, MH, JP（左三）、中華環保聯合會副主任陳永暉先生（右二）、中國科學院北京中科科技創新發展研究院數字低碳研究所所長陳偉光博士（右一），以及香港科技大學化學及生物工程學系、環境及可持續發展學部教授楊經倫教授（左二）。飛灰資源化技術勢成推動大灣區循環經濟發展的關鍵引擎隨後進行的「化廢為寶、產業升級、灣區共創」科技論壇，匯聚多位來自不同領域的專家學者與業界代表，圍繞三大主題進行深入交流，為綠色科技與灣區產業升級注入嶄新洞見。《中華人民共和國固體廢物污染環境防治法》等法律法規對飛灰的處置和利用作出了明確規定，要求對飛灰進行無害化、資源化利用，减少對環境的污染。湖南建投六建集團海外公司副經理黃菁女士詳細剖析飛灰、污泥等多源固廢綜合治理與新材料融合的優勢及案例。中國科學院北京中科科技創新發展研究院數字低碳研究所所長陳偉光博士指出，2030年起全國逐步減少飛灰填埋量，鼓勵實現零填埋。針對飛灰中的氯鹽、重金屬等污染物，現有整合填埋方式將被創新技術取代，通過二步法工藝實現資源化轉型，構建完整產業價值鏈，為全球固廢近零填埋提供可行路徑。論壇主持人APEL主席鍾偉强博士（左）與中國科學院北京中科科技創新發展研究院數字低碳研究所所長陳偉光博士（中）及湖南建投六建集團海外公司副經理黃菁女士（右）共同探討廢物資源化與循環科技。在新型工業化與智能製造方面，香港生產力促進局新型工業化部總經理單銘賢工程師及生物醫學專家顧問蔡永達博士分享了自動化、數字化和AI驅動的工業升級方案。香港生產力促進局新型工業化部總經理單銘賢工程師表示：「香港正邁向『新質時代』，特區政府推出的『新型工業化資助計劃（NIFS）』和『新型工業加速計劃（NIAS）』，旨在資助智能及綠色製造的企業在香港設立新智能生產線。生產力局亦通過提供一系列未來技能培訓培育未來工程師，並推動新能源、生物健康、先進製造、新材料及人工智能等新興領域的發展，鞏固香港國際創新中心地位。」香港生產力促進局新型工業化部生物醫學專家顧問蔡永達博士表示：「生產力局在推動香港生命健康及新能源產業研發成果商業化所進行的措施和項目中，與一家本地企業合作以促進氫能產業的發展，計劃興建香港首座綠色製氫設施，利用堆填區產生的天然沼氣製氫。該設施所生產的氫氣符合GB/T 37244-2018質量標準，純度≥99.97%，除了供交通運輸使用，亦適用於其他下游應用場景。」論壇主持人APEL主席鍾偉强博士（左）與香港生產力促進局新型工業化部總經理單銘賢工程師（中）及香港生產力促進局新型工業化部生物醫學專家顧問蔡永達博士（右）共同探討新型工業化與智能製造議題。關於智能水務創新成果，香港科技大學化學及生物工程學系、環境及可持續發展學部副教授韓偉教授及香港科技大學 (HKUST)--Absolute Pure EnviroSci Limited (APEL) 聯合實驗室首席應用科學家陸朗霆先生則分享了智能水質監測及高效淨化技術的最新突破。陸朗霆先生表示：「水資源是維繫人類生命與生態環境健康的關鍵。APEL 研發的 Wisepura Aquapura 採用了全球首創的多孔結構矽微囊專利技術，與水接觸時智能控釋其活性物質，有效針對供水系統、空調系統及下水道系統中超過 30 種細菌、真菌及病毒，同時滿足多種應用場景的需求。目前，這項創新技術已在香港多處公共基礎設施廣泛應用。更重要的是，矽微囊系統可多次循環使用，且在使用壽命結束後能安全處理，有效減輕環境負擔。」香港科技大學化學及生物工程學系、環境及可持續發展學部副教授韓偉教授（左）及香港科技大學 (HKUST)--Absolute Pure EnviroSci Limited (APEL) 聯合實驗室首席應用科學家陸朗霆先生（右）於論壇上分享了智能水質監測及高效淨化技術的最新突破。關於中華環保聯合會中華環保聯合會是經國務院批准、民政部註冊，生態環境部為行業管理部門，由熱心環保事業的人士、企業、事業單位自願結成的、非營利性的、全國性的社團組織。中華環保聯合會的宗旨是圍繞實施可持續發展戰略，圍繞實現國家環境與發展的目標，圍繞維護公眾和社會環境權益，充分體現中華環保聯合會「大中華、大環境、大聯合」的組織優勢，發揮政府與社會之間的橋梁和紐帶作用，促進中國環境事業發展，推動全人類環境事業的進步。關於大灣區經貿協會大灣區經貿協會是由社會精英倡導創立的經濟貿易及融資配對平台，願景及使命是配合國家政策，致力推動大灣區的經濟發展。積極為各個領域提供商業、經濟和融資配對服務，搭建起企業與政府、企業與企業之間的橋樑，促進大灣區成為全球領先的經濟體。關於大灣區學院大灣區學院由大灣區經貿協會創辦，目的是配合國家的粵港澳大灣區戰略規劃發展，培育環球企業領袖人才，維持香港作為首屈一指的國際金融中心；並與國際知名高等學府聯合舉辦高端人才培訓認證課程「大灣區院士」，與及頒授榮譽名銜予對社會及大灣區建設有傑出貢獻的政、商、學界知名人士。關於APELAbsolute Pure EnviroSci Limited（「APEL」）為香港聯合交易所主板上市公司--義合控股有限公司（香港主板上市編號：1662）的間接非全資附屬公司。以改善生活品質及居住環境為使命， APEL 主要從事健康與環境科技創新的研究、開發及商業化。基於其多層次殺菌塗層技術（MAP-1），APEL 已在四個關鍵領域：飛機空氣淨化、水質淨化、畜牧健康和環保建材，研發專門的應用配方，旨在應對全球迫切挑戰。2024 年 1 月 10 日，APEL與香港科技大學共同建立「香港科技大學--APEL 環境科學健康與環境創新聯合實驗室」，就創新的健康和環境技術進行研發及成果轉化。APEL 期待與全球研究人員和行業夥伴合作，推動更多健康與環境科技創新。為佈局國際健康與環境衛生的市場，APEL 現正於大阪 The Lab.舉行創新互動展覽會，展示三大旗艦產品--Wisepura 水質及空氣淨化系統、GERMAGICTM 抗菌塗層和 GERMAGICTM PET 寵物健康及護理方案，把握亞洲健康科技產業的發展機遇。如有垂詢，請聯絡：AJA (IR & Communications)庾婉華電話：(852) 9500 4443電郵：avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.